Reducing the risk of blood clots in artificial heart valves
(University of Bern) People with mechanical heart valves need blood thinners on a daily basis, because they have a higher risk of blood clots and stroke. Researchers at the ARTORG Center of the University of Bern, Switzerland, now identified the root cause of blood turbulence leading to clotting. Design optimization could greatly reduce the risk of clotting and enable these patients to live without life-long medication. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - January 13, 2020 Category: International Medicine & Public Health Source Type: news
Medtech in a Minute: LivaNova Nixes TMVR, FDA Tackles EtO, and More
FDA Wants Medtech to Cut Back on EtO Use
FDA is encouraging manufacturers to reduce the amount of paper included in sterile device packaging in order to reduce the amount of ethylene oxide (EtO) required for effective sterilization. A new voluntary master file program also aims to speed up approval of sterilization site relocations and the implementation of methods that reduce the amount of EtO needed to sterilize FDA-approved medical devices.
Â
LivaNova Says Sayonara to TMVR
LivaNova is scrapping its Caisson transcatheter mitral valve replacement program because of continued...
Source: MDDI - November 27, 2019 Category: Medical Devices Authors: Amanda Pedersen Tags: Business Source Type: news
LivaNova Stops Caisson TMVR Program
LivaNova is scrapping its Caisson transcatheter mitral valve replacement (TMVR) program because of declines its heart valve business has seen over the last five years. Plans now call for the London-based company to enter into a restructuring plan for its heart valve business, which brought in $130 million in revenue in 2018.
Under the restructuring plan, it is expected that about 150 employees could be potentially impacted in the three sites of Saluggia, Vancouver, and Minneapolis. LivaNova’s Saluggia, Italy facility will now become dedicated to R&D and production of mechanical heart valves, rings, ac...
Source: MDDI - November 21, 2019 Category: Medical Devices Authors: Omar Ford Tags: Cardiovascular Source Type: news
Early Menopause Increases Heart Risks
Menopause before age 40 increased the risk for coronary artery disease, heart failure, blood clots and heart valve problems. (Source: NYT Health)
Source: NYT Health - November 21, 2019 Category: Consumer Health News Authors: Nicholas Bakalar Tags: Menopause Heart Source Type: news
Edwards SAPIEN 3 TAVI Receives Expanded Approval In Europe
Superior TAVI Valve Indicated for All Patients Diagnosed with Aortic Stenosis
IRVINE, Calif., Nov. 6, 2019 -- (Healthcare Sales & Marketing Network) -- Edwards Lifesciences Corporation (NYSE: EW), the global leader in patient-focused innovations for st... Devices, Interventional, Cardiology, Regulatory Edwards Lifesciences, SAPIEN 3, transcatheter, heart valve, aortic valve (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - November 6, 2019 Category: Pharmaceuticals Source Type: news
Cardiac rehab after heart valve surgery tied to better outcomes
(Reuters Health) - Cardiac rehab, known to be helpful after heart attacks, may also aid recovery from heart valve surgery, a study suggests. (Source: Reuters: Health)
Source: Reuters: Health - October 31, 2019 Category: Consumer Health News Tags: healthNews Source Type: news
4 core applications of cardiovascular 3D printing
How are clinicians integrating 3D printing technology into adult cardiovascular...Read more on AuntMinnie.comRelated Reading:
3D-bioprinted model mimics real human heart properties
4D flow MRI, 3D printing improve congenital heart surgery
3D printing technique improves heart valve sizing
3D printing bolsters care for congenital heart disease
Flexible 3D-printed heart replicates size, texture (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - October 28, 2019 Category: Radiology Source Type: news
3Q19 Earnings Show Edwards Continues to Have Solid TAVR Story
Edwards Lifesciences made tremendous gains in 3Q19 by toppling consensus forecast and significantly raising revenue. As a result, shares of Edwards jumped by nearly 6%.
The Irvine, CA-based company, often called a pioneer in the transcatheter aortic valve replacement (TAVR) market, improved third quarter net sales 20.7% year-over-year to $1.09 billion. Diluted earnings per share for the quarter were $1.30, while adjusted earnings per share grew 32% to $1.41.
For 2019, the company now expects total sales around the top of its previous $4 billion to $4.3 billion range. Additionally, the company raised its full-year 2019 adju...
Source: MDDI - October 24, 2019 Category: Medical Devices Authors: Omar Ford Tags: Business Cardiovascular Source Type: news
Community Health Workers Are Vital; Governments Should Be Paying Them
Illness is universal, health care is not. Over half of the world’s 7.3 billion people, including 1 billion in rural communities, lack access to health care. Approximately 13 million children still go without a single dose of any vaccine. Nearly 9 million newborns, children and mothers still die each year from preventable or treatable conditions.
Compounding this crisis is a massive health-worker shortage, forecast to grow to 18 million by 2030. Training more doctors is necessary, but because doctors are concentrated in cities, they alone are insufficient to close this gap. What if the residents of rural communities&#...
Source: TIME: Health - October 24, 2019 Category: Consumer Health News Authors: Dr. Raj Panjabi Tags: Uncategorized Healthcare Source Type: news
A Blood Filter Fights Deadly Inflammatory Response
A new blood filtration technology may prove to be life-saving for patients whose normally healthy inflammatory response to injury or illness has gone into overdrive, resulting in fatally high levels of cytokines in their blood. In an interview with MD+DI, Dr. Phillip Chan, MD, PhD, CEO of CytoSorbents Corp., explained that inflammation, and the production of substances called cytokines that drive inflammation, are the body’s natural response to heal injury or infection. But sometimes, the inflammatory response is so severe in such conditions as sepsis and infection, burn injuries, trauma, pancreatitis, li...
Source: MDDI - October 9, 2019 Category: Medical Devices Authors: Susan Shepard Tags: Cardiovascular Source Type: news
New Data Demonstrate Strong Outcomes for Abbott Device to Repair Leaky Tricuspid Heart Valves
- New data presented at TCT 2019 on Abbott's TriClip device from the TRILUMINATE Feasibility Study met both the primary safety and performance endpoints (Source: Abbott.com)
Source: Abbott.com - September 28, 2019 Category: Pharmaceuticals Source Type: news
Abbott ’s Pediatric Cardiovascular Devices Gain CE Mark
Abbott Laboratories is bringing two of its pediatric devices in the cardiology space to Europe. The Abbott Park, IL-based company has received CE mark for both the Masters HP 15mm rotatable mechanical heart valve and the Amplatzer Piccolo Occluder.
The Masters valve is the world's smallest mechanical heart valve and allows doctors to treat babies and toddlers in need of a mitral or aortic heart valve replacement. Until Abbott's device, surgeons could only use a range of larger-sized valves to replace a pediatric heart valve that could not be repaired, which could result in improper fit and complications. The Masters pediat...
Source: MDDI - September 18, 2019 Category: Medical Devices Authors: Omar Ford Tags: Cardiovascular Source Type: news
Abbott Announces European Approval of Two Life-saving Heart Devices for Babies and Children
World's smallest pediatric treatments pioneered by Abbott address critical needs for the most vulnerable patients: babies and children born with common congenital heart defects
Includes pediatric mechanical heart valve and first minimally invasive devic... Devices, Cardiology, Regulatory Abbott, Masters HP, Amplatzer Piccolo, patent ductus arteriosus (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - September 17, 2019 Category: Pharmaceuticals Source Type: news
Antibiotics Tied to Heart Valve Problems
The class of antibiotics called fluoroquinolones (Cipro, Levaquin and others) may increase the risk of heart valve problems. (Source: NYT Health)
Source: NYT Health - September 17, 2019 Category: Consumer Health News Authors: Nicholas Bakalar Tags: Antibiotics Heart Levaquin (Drug) Source Type: news
Abbott Launches World's First Pivotal Trial to Test New Approach for Repairing Leaky Tricuspid Heart Valves
- TRILUMINATE Pivotal trial is the world's first randomized clinical trial to evaluate transcatheter tricuspid valve repair in patients with severe tricuspid regurgitation (Source: Abbott.com)
Source: Abbott.com - September 5, 2019 Category: Pharmaceuticals Source Type: news
